Comparison of Fixed Cell-based Assay to Radioimmunoprecipitation Assay for Acetylcholine Receptor Antibody Detection in Myasthenia Gravis. (5th December 2022)

• Record Type: Journal Article
• Authors: Mirian, Ario; Nicolle, Michael; Budhram, Adrian
• Is Part Of: Neurology. Volume 99:Number 23(2022)Supplement 2
• Page Start: S72
• Page End: S72
• Publication Date: 2022-12-05
• Subjects: Neurology -- Periodicals; Neurology -- Periodicals; Neurologie -- Périodiques; 616.8
• DOI: 10.1212/01.wnl.0000903576.06122.e0
• Languages: English
• ISSNs: 0028-3878

Abstract

Abstract : Objective: To compare specificity and sensitivity of a commercially available fixed cell-based assay (F-CBA) to radioimmunoprecipitation assay (RIPA) for acetylcholine receptor antibody (anti-AChR) detection in myasthenia gravis (MG). Background: Approximately 50% of ocular and 85% of generalized MG are anti-AChR positive by RIPA, the current gold standard test. Clustered live cell-based assay (L-CBA) can detect low-affinity anti-AChR that are missed by RIPA, but the costly and time-consuming nature of L-CBA has restricted its use to specialized centres. A commercial F-CBA has become available for anti-AChR detection, but its diagnostic performance compared to RIPA requires evaluation. Design/Methods: In this retrospective diagnostic cohort study we reviewed the clinical information of suspected MG patients evaluated at London Health Sciences Centre MG clinic, who were clinically classified as MG or non-MG and who had anti-AChR RIPA and then F-CBA performed. Classification of each patient as anti-AChR F-CBA-negative/positive, RIPA-negative/positive, and MG/non-MG permitted specificity and sensitivity calculations for each assay. Results: Six-hundred-eighteen patients were included in study analysis. The median patient age at time of sample collection was 45.8 years (range: 7.5–87.5 years) and 312/618 (50.5%) were female. Of 618 patients, 395 (63.9%) were classified as MG. Specificity of both F-CBA and RIPA was excellent (99.6% vs. 100%, P > 0.99). One F-CBA-positive patient was classified as non-MG, although in retrospect ocular MG with functional overlay was challenging to exclude. Sensitivity of F-CBA was significantly higher than RIPA (76.7% vs. 72.7%, P = 0.002). Overall, 20/97 (21%) otherwise SNMG patients after RIPA evaluation had anti-AChR detected by F-CBA. Conclusions: In our study anti-AChR F-CBA and RIPA both had excellent specificity, while F-CBA had 4% higher sensitivity for MG and detected anti-AChR in 21% of SNMG patients. Our findings indicate that F-CBA is a viable alternative to RIPA for anti-AChR detection.